Abstract:

Treatment of neurosurgical intensive care patients infected with multidrug resistant (MDR) or extensive drug resistant (XDR) Acinetobacter baumannii presents significant challenges and is associated with high mortality rates. Sulbactam has long been an effective treatment for MDR Acinetobacter baumannii, particularly due to its ability to penetrate the inflamed blood-brain barrier, making it highly suitable for use in severe neurosurgical cases. However, in recent years, increasing resistance to sulbactam among Acinetobacter baumannii strains has become a concern. There is a lack of standardized guidelines regarding the dosage, administration methods, routes and combination therapy strategies for sulbactam in the treatment of these resistant infections. Thus, Chinese Neurosurgical Intensive Care Management Collaborative Group has developed the "Chinese expert consensus on the use of sulbactam to treat patients infected with Acinetobacter baumannii in the neurosurgical intensive care unit", through a thorough review of relevant evidence-based medical literature and extensive discussion and revision. This consensus includes 28 recommendations aimed at providing scientific and feasible clinical guidance for the application of sulbactam in the management of neurosurgical intensive care patients.

Key words: Neurosurgical procedures, Critical care, Acinetobacter baumannii, Sulbactam, Diagnostic and treatment guideline

摘要：

多重耐药或广泛耐药鲍曼不动杆菌感染的神经外科重症患者治疗难度大、病死率高。舒巴坦是治疗多重耐药鲍曼不动杆菌感染的有效药物，具有穿透炎性血脑屏障的优势，适用于神经外科重症患者。近年随着鲍曼不动杆菌对舒巴坦的耐药趋势日益严峻，舒巴坦治疗多重耐药或广泛耐药鲍曼不动杆菌感染药物剂量、给药途径、联合方案等缺乏规范化标准。中国神经外科重症管理协作组通过梳理相关循证医学证据并经过反复讨论修改后形成《舒巴坦治疗神经外科重症患者鲍曼不动杆菌感染中国专家共识》，涵盖28条共识建议，为舒巴坦在神经外科重症管理中的应用提供科学、可行的临床指导。

关键词: 神经外科手术, 危重病人医疗, 鲍氏不动杆菌, 舒巴克坦, 诊疗指南